Core Viewpoint - Analysts project that Colgate-Palmolive (CL) will report quarterly earnings of 0.86pershare,unchangedyearoveryear,withrevenuesexpectedtodeclineby3.84.87 billion [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.2% lower over the last 30 days, indicating a collective reevaluation by analysts [2]. - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Net Sales- Pet Nutrition' to reach 1.09billion,reflectingadecreaseof0.83.77 billion, indicating a decline of 4.9% from the previous year [5]. - 'Net Sales- Oral, Personal and Home Care- North America' is expected to be 1.00billion,showingaslightincreaseof0.41.09 billion, suggesting a significant decline of 12.6% year over year [6]. - 'Net Sales- Oral, Personal and Home Care- Africa/Eurasia' is projected to be 273.66million,downby0.9674.15 million, indicating a decrease of 5.2% from the prior year [7]. - 'Net Sales- Oral, Personal and Home Care- Asia Pacific' is projected at 727.36million,reflectingaslightincreaseof0.11.01 billion, down from 1.04billionyearoveryear[8].−′Operatingprofit−PetNutrition′isprojectedat239.30 million, an increase from 199millioninthepreviousyear[8].−′Operatingprofit−Oral,PersonalandHomeCare−NorthAmerica′isestimatedat209.78 million, down from 222millionyearoveryear[9].−′Operatingprofit−Oral,PersonalandHomeCare−LatinAmerica′isexpectedtobe364.08 million, compared to 405millionlastyear[9].−′Operatingprofit−Oral,PersonalandHomeCare−Africa/Eurasia′isprojectedat66.32 million, slightly up from $66 million in the same quarter last year [10]. Stock Performance - Colgate-Palmolive shares have increased by 4.2% over the past month, contrasting with the S&P 500 composite's decline of 8.9% [10].